Biofusion expands University of Sheffield deal
This article was originally published in Scrip
Biofusion, a UK university IP commercialisation company, has expanded its existing 10-year exclusive agreement with the University of Sheffield, UK, to include the rights to commercialise all non-life science research-generated intellectual property. It has also decided to change its name to Fusion IP to more accurately reflect its enlarged business. In addition, the company has raised just over £2 million before expenses through a placing of 2.3 shares at 90 pence each. The company's original agreement, which covers only life science-related IP, is due to expire in 2015.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.